Cerebrolysin REGistry Study in Stroke

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02541227
• Date of registration: 28/08/2015
• Prospective Registration: No
• Primary sponsor: Ever Neuro Pharma GmbH
• Public title: Cerebrolysin REGistry Study in Stroke CREGS-S
• Scientific title: Cerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic Stroke
• Date of first enrolment: May 2014
• Target sample size: 1823
• Recruitment status: Active, not recruiting
• URL: https://clinicaltrials.gov/show/NCT02541227
• Study type: Observational [Patient Registry]

Countries of recruitment

Austria

Contacts

• Name: Kennedy Lees, MD
• Affiliation: University of Glasgow

Key inclusion & exclusion criteria

Inclusion Criteria:

- Signed informed consent

- Clinical diagnosis of acute ischemic stroke

- Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)

- Reasonable expectation of successful follow-up (max. 100 days)

Exclusion Criteria:

- none



Age minimum: N/A
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Ischemic Stroke

Intervention(s)

Drug: Cerebrolysin

Primary Outcome(s)

Modified Rankin Scale [Time Frame: 90 days]

Secondary Outcome(s)

Montreal Cognitive Assessment (MoCA) [Time Frame: 90 days]

Home Time (number of nights among the first 90 days after stroke onset that the patient spends in his own or a relative's private home) [Time Frame: 90 days]

The National Institutes of Health Stroke Scale (NIHSS) [Time Frame: 90 days]

Secondary ID(s)

EVER-GB-0514

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

SITS International